Programação

Novos Negócios como Agente Estratégico no Desenvolvimento da Indústria Farmacêutica

Programa

8.30 – 8.50hs: Credenciamento e Welcome Coffee

9.00 – 9.50hs: Navigating the Complexities of Raising Capital to Fund a LatAm-Based Pharma or Biosimilar Business Seeking to Access the US Market – Kristopher Brown

9.50 – 10.40hs: Benefícios e Mecanismos de Apoio à Internacionalização de Negócios Junto à Indústria Farmacêutica – Bruno Aguiar

10.40 – 11.00hs: Coffee-Break

11.00 – 11.50hs: Indústria Farmacêutica e Sustentabilidade: Pontos Relevantes que Podem Afetar as Atividades de Novos Negócios – Hagop Barsoumian

11.50 – 12.40hs: Optimizing and Structuring Complex Collaboration and Licensing Deals to Pave the Way to a Successful Structured M&A Exit – Jonathan Schur

12.40 – 13.00hs – Debate

13.00 – 14.15hs – Almoço

14.30 – 18.30hs – Reuniões “Um a Um”

Palestrantes

Bruno Henrique Coutinho de Aguiar

Bruno Henrique Coutinho de Aguiar

É advogado graduado pela Faculdade de Direito da Universidade de São Paulo (USP) e especialização em Finanças e Investment Banking pela Fundação Instituto de Administração (FIA). Possui ainda especialização em Direito de Empresa (Administração Empresarial e Tributária) pela Universidade de São Paulo (USP). Atualmente é sócio no Rayes & Fagundes Advogados.

Hagop Barsoumian

Hagop Barsoumian

Atuou por 16 anos como gerente geral de farmacêuticas multinacionais e em cargos de diretoria em laboratórios nacionais, além de acumular atividades no terceiro setor como diretor executivo no Instituto Saúde e Sustentabilidade e gestor voluntário junto à diretoria do Instituto Butantan. Foi conselheiro do Conselho Diretor do Sindusfarma por 9 anos e membro do Conselho da Interfarma por 4 anos. Atualmente está cursando mestrado em Sustentabilidade com linha de pesquisa em Ciência e Tecnologia Ambiental na Escola de Artes, Ciências e Humanidades da Universidade de São Paulo (USP).

Jonathan Schur

Jonathan Schur

Is a partner in Goodwin’s Life Sciences group. Mr. Schur advises pharmaceutical and medical device companies in structuring collaborations, mergers, acquisitions and divestitures, and advancing products from discovery until commercialization. He has significant experience in cross-border transactions and is known for his ability to bring parties of transactions together, effectively bridging legal and cultural differences, in particular between European and U.S. companies. He also works with clients to arrange venture and later-stage financing, as well as representing them pre-IPO and at the IPO stage. Mr. Schur counsels companies with activities that cross the Atlantic or Pacific on legal and management issues that need to be addressed to ensure efficient operations and achieve regulatory compliance. This includes the regulatory aspects of product and pricing authorizations, clinical trials, agreements with hospitals and physicians, privacy and marketing practices in the life sciences sector.

Kristopher Brown

Kristopher Brown

Is a partner in the Goodwin’s Life Sciences group. Mr. Brown negotiates and structures private equity and venture capital financing transactions. He also advises on corporate and transactional matters for numerous financial and corporate strategic investors as well as emerging growth companies in the life sciences, healthcare, financial and technology sectors. Mr. Brown has experience in the full range of complex commercial transactions, including mergers and acquisitions, divestitures, public offerings, licensing transactions, the formation of investment partnerships, and the creation of strategic and collaborative alliances and joint ventures. Practicing for more than 20 years, Mr. Brown has advised on more than 250 transactions in the life sciences sector alone. In addition, he counsels investors, management executives, and boards of directors on governance and regulation issues and securities law matters.